Investor Center
Company Profile
Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. We plan to source these development candidates from both our internal drug discovery programs and our in-licensing efforts. We believe that we are well-positioned to create shareholder value through our development activities given the ability to achieve clinical proof-of-concept relatively quickly and cost-effectively in these disease areas.
Recent Releases
Jul 17, 2008
Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference
Jul 9, 2008
Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
Events
May 22, 2008 9:30 AM
Annual Shareholders' Meeting
Mar 18, 2008 8:00 AM
Ardea Biosciences Conference Call
Mar 18, 2008 4:40 PM
Cowen and Company 28th Annual Health Care Conference
Fact Sheet
Presentations
 |
March 2008 |
Posters
RDEA119, A Selective MEK 1/2 Inhibitor Ameliorates Experimental Arthritis
RDEA119, A Potent and Highly Selective MEK Inhibitor Ameliorates Murine Colitis
RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties
RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies
A Novel NNRTI Class with Potent Anti-HIV Activity
RDEA427 and 640 Novel NNRTIs - Potent Activity
RDEA806 IQ Assessment Potent NNRTI
A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer
The Discovery of RDEA806, a Potent New HIV NNRTI
RDEA806, a Potent NNRTI with a High Genetic Barrier to Resistance
